The biotech halted dosing in two study arms after finding instances of pericardial effusion in testing of its drug, which analysts have viewed as a potential threat to Merck’s Winrevair.
The biotech halted dosing in two study arms after finding instances of pericardial effusion in testing of its drug, which analysts have viewed as a potential threat to Merck’s Winrevair.
